Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol. 2010 Oct; 5(10):1644-8.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibiotics, Antineoplastic
Clinical Trials, Phase I as Topic
Depsipeptides
Drug Resistance, Neoplasm
Female
Histone Deacetylases
Humans
Lung Neoplasms
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Salvage Therapy
Small Cell Lung Carcinoma
Survival Rate
Treatment Outcome

authors with profiles

Everett E. Vokes